Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027.

That's the title that Science magazine is bestowing upon the medication called lenacapavir — a twice yearly injectable that ...

Two friends are taking on a mission assist families that have been affected by domestic violence homicides. Dr. Cheryl ...

Here at Zacks, we focus on our proven ranking system, which places an emphasis on earnings estimates and estimate revisions, to find winning stocks. But we also understand that investors develop their ...

Gilead plans to begin Phase 3 testing soon for a drug it believes could prevent HIV infection with a single shot every year ...

(Tozzi, 12/11) In other pharma and tech news — Stat: Gilead To Test Once-A-Year HIV Prevention Shot Gilead said Tuesday that it will soon begin Phase 3 testing for a drug it believes could prevent HIV ...

Gilead Sciences (GILD) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Palbociclib plus ET improved outcomes over chemotherapy ± ET maintenance in patients with high-risk, HR+, HER2- metastatic breast cancer.

Price increases for five of the 10 drugs that contributed the most to a rise in U.S. medical spending in 2023 were not ...

In a report released today, Joseph Catanzaro from Piper Sandler maintained a Buy rating on Gilead Sciences (GILD – Research Report), with a ...

Northmor's A.J. Bower was named OPSMA D-VI Offensive Player of the Year for 2024. Here are other Marion-area football players ...

FirstLight, a leading provider of digital infrastructure services to enterprise and carrier customers throughout the Northeast and mid-Atlantic, has finalized an agreement with the Maine Connectivity ...